|
Step 1
|
Step 1 Unknown
|
Step 1 EPHA2−
|
Step 1 EPHA2+
|
Step 1 EPHA22+
|
Step 1 EPHA23+
|
Step 2
|
Step 2 EPHA2−
|
Step 2 EPHA2+
|
Step 2 EPHA22+
|
Step 2 EPHA23+
|
---|
(N = 21)
|
(N = 3)
|
(N = 9)
|
(N = 2)
|
(N = 6)
|
(N = 1)
|
(N = 15)
|
(N = 0)
|
(N = 0)
|
(N = 13)
|
(N = 2)
|
---|
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
N (%) [95% CI]
|
---|
Complete response
|
0 (0.0) [0.0–16.1]
|
0 (0.0) [0.0–70.8]
|
0 (0.0) [0.0–33.6]
|
0 (0.0) [0.0–84.2]
|
0 (0.0) [0.0–45.9]
|
0 (0.0) [0.0–97.5]
|
0 (0.0) [0.0–21.8]
|
0 (0.0) [n.d.]
|
0 (0.0) [n.d.]
|
0 (0.0) [0.0–24.7]
|
0 (0.0) [0.0–84.2]
|
Partial response
|
0 (0.0) [0.0–16.1]
|
0 (0.0) [0.0–70.8]
|
0 (0.0) [0.0–33.6]
|
0 (0.0) [0.0–84.2]
|
0 (0.0) [0.0–45.9]
|
0 (0.0) [0.0–97.5]
|
1 (6.7) [0.2–31.9]
|
0 (0.0) [n.d.]
|
0 (0.0) [n.d.]
|
1 (7.7) [0.2–36.0]
|
0 (0.0) [0.0–84.2]
|
Stable disease
|
7a (33.3) [14.6–57.0]
|
2 (66.7) [9.4–99.2]
|
3 (33.3) [7.5–70.1]
|
1 (50.0) [1.3–98.7]
|
1 (16.7) [0.4–64.1]
|
0 (0.0) [0.0–97.5]
|
6 (40.0) [16.3–67.7]
|
0 (0.0) [n.d.]
|
0 (0.0) [n.d.]
|
5 (38.5) [13.9–68.4]
|
1 (50.0) [1.3–98.7]
|
Progressive disease
|
14a (66.7) [43.0–85.4]
|
1 (33.3) [0.8–90.6]
|
6 (66.7) [29.9–92.5]
|
1 (50.0) [1.3–98.7]
|
5 (83.3) [35.9–99.6]
|
1 (100.0) [2.5–100.0]
|
8 (53.3) [26.6–78.7]
|
0 (0.0) [n.d.]
|
0 (0.0) [n.d.]
|
7 (53.8) [25.1–80.8]
|
1 (50.0) [1.3–98.7]
|
- Abbreviations: EPHA2 erythropoietin-producing hepatocellular receptor A2, CI confidence interval, n.d not determined
- aIncludes patients with unknown EPHA2 status